Home » Blog » Lab Story – Megan Smith
Lighthouse Labs
Oncology
Greatly Enhancing the Capacity for ...
Detecting tumour DNA through liquid biopsies marks the new frontier in oncology, providing a wealth of critical data for drug development research.
Dr Andrzej Rutkowski, Lead Scientist at Medicines Discovery Catapult (MDC), illuminates the value of this pioneering approach.
Jump to Optimised Analysis of ctDNA Jump to Customised and Differentiated Personalised Medicine Development Solutions
Medicines Discovery Catapult and Xe...
Click here to see more
Opinion
Chris Molloy, CEO, Medicine...
Syndicates
PIPE-CF
We caught up with Dr Jo Fothergill, Senior Lecturer at the University of Liverpool and…
People Power
Dhifaf shares with us her e...
Which team do you work in and what does that team do? I work…
Mike gives us an insight in...
Juliana shares her 13 years...
Complex Medicines
Complex Medicines: A Snapshot into ...
Offering clarity to the sco...
Lighthouse People Power
Ria shares with us one impo...
Read about Samantha's exper...
Find out how Ian became a s...
Read about what inspired Sa...
Read about Beverley's love ...
Matt shares with us why mov...
Read what some of our femal...
Read about Hervé's role as...
Michael shares with us what...
Science & Technology
World Antimicrobial Awarene...
Discover how Emily's role a...
MDC Connects: A Guide to Drug Discovery 2020
The importance of clinical ...
Accessing immune function
Thinking about biomarkers e...
Using complex cell models i...
A practical guide for the p...
The importance of thinking ...
From teaching in Africa to ...
The advantages and disadvan...
Importance of understanding...
Outlining the consideration...
How PK-PD modelling can be ...
Lessons for efficacy studie...
The approaches for evaluati...
The different skills requir...
A case study of approaches ...
How the formulation of a co...
How imaging technologies ca...
Common mistakes made and ho...
What to do, what not to do
Generating good quality pro...
How structure based and lig...
How the emerging field of C...
Discovering hits faster and...
NanoBRET and PROTAC
A critical starting point f...
Learn about Gayle's journey...
How informatics and data mi...
The importance of selecting...
Views from the Discovery Nation
Nucleic acid therapeutics h...
PROTAC (PROteolysis TArgeti...
Lighthouse Lab Stories
Sarah talks about her aspir...
Health Data
An introduction to the appl...
A new toolkit from the MRC ...
Outputs from the workshop h...
The understanding of how to...
Co-editing a special issue ...
Kepa brings 15 years' exper...
Chris Molloy’s insightful...
The importance of developin...
Anna shares her passion for...
Computational chemistry is ...
It is estimated to affect 1...
Significant improvements ha...
What is it, and why do we n...
Exploring classification an...
The industry's untapped are...
Exploring kinase compound p...
Part one: Unlocking hidden ...
Informatics
What do Netflix and drug di...
Making in silico dru...
Paving the way for successf...
The challenges and triumphs...
Moving forward - implementi...
A view from the 2019 Bionow...
Using cross validation in a...
Cancers give away their wea...
An interview with Richard S...
Stem cell biology has quick...
Despite some bandwagon jump...
The most exciting time in h...
Accelerating progress and i...
5 key things to consider be...
Maximising the value for bo...
Finding rare and needs-spec...
Drug companies are turning ...
Real-world fact or science ...
A real-world case study to set the scene Timothy Omer is a Type 1 diabetic…
Keeping secrets in drug discovery
SMEs in the life sciences sector are the lifeblood of new innovations. If that’s you,…
Putting the human back into medicin...
Is there something missing from your research? The need to humanise drug discovery was highlighted…
Our CEO Chris Molloy reflec...
Catapult CEO Chris Molloy reflects on the latest trends and debates from BIO 2017 The…
The importance of collaboration
A guest blog from Aisling Burnand, CEO of The Association of Medical Research Charities Collaboration…
Catapult open for business to suppo...
New £1m facilities at University of Warwick open to support collaborative drug discovery, announces CEO…
The Time is Now!
CEO Chris Molloy celebrates 100 days at the Medicines Discovery Catapult It is 100 days…
We don’t know everything, but...
Board Member Peter Kellner writes about the role of the Medicines Discovery Catapult and the…
A new approach for 2017
As 2017 begins, we are looking forward to new beginnings, new ways of thinking and…
A problem shared…
CEO Chris Molloy explains why collaboration is essential to the discovery of new and effective…
Putting Patients First
CEO Chris Molloy explains why patients and medical research charities are so vital to the…
Medicines technology: bringing inno...
Incoming Chief Executive for the Medicines Discovery Catapult, Chris Molloy, gives his thoughts on the…
Kate Bellingham: Championing girls&...
Kate Bellingham, Medicines Discovery Catapult Board Member, is a passionate champion for girls’ opportunities in…
The Medicines Discovery Catapult: a...
The Medicines Discovery Catapult is embarking on an exciting journey as the first of its…
